>Let's see here, Solvay owns a small testosterone topical drug called androgel and they leave behind an endometriosis drug before seeing results of the trials. Does anyone else know a company with a testosterone drug (in PII) and an endomtriosis drug (in PII)??. Maybe Solvay has just become the number one suitor for little old Repros therapeutics!!!<
This is extremely logical. LHRH's are dead for endometriosis and uterine fibroids if Proellex makes it to market. And Androgel is dead if Androxal makes it to market.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.